Table of Contents
More than 50% of all cancers - and many other diseases - are associated with breakdowns in the chromatin regulatory system.
It's the machinery that opens and closes the right sections of DNA at the right time. When it breaks, gene expression goes off-script - and disease follows.
Foghorn Therapeutics' Gene Traffic Control platform finds the genetic dependencies cancers rely on for survival, then drug them with enzyme inhibitors, targeted protein degraders, and transcription factor disruptors.
The lead clinical program, FHD-909 (LY4050784), is a first-in-class, oral, SMARCA2-selective small molecule being developed for SMARCA4-mutated cancers, with preclinical anti-tumor activity in SMARCA4-mutant lung tumor models.
At JPM 2026, Onyx caught up with CEO Adrian Gottschalk to find out more.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
Comments